205 related articles for article (PubMed ID: 36479043)
1.
Wang C; Yin Y; Sun Z; Wang Y; Li F; Wang Y; Zhang Z; Chen X
Dis Markers; 2022; 2022():2334338. PubMed ID: 36479043
[TBL] [Abstract][Full Text] [Related]
2. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of PSAT1 inhibits cell proliferation and migration in uterine corpus endometrial carcinoma.
Wang M; Yue S; Yang Z
Sci Rep; 2023 Mar; 13(1):4081. PubMed ID: 36906716
[TBL] [Abstract][Full Text] [Related]
4. ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma.
Krakstad C; Tangen IL; Hoivik EA; Halle MK; Berg A; Werner HM; Ræder MB; Kusonmano K; Zou JX; Øyan AM; Stefansson I; Trovik J; Kalland KH; Chen HW; Salvesen HB
Oncotarget; 2015 Sep; 6(29):28440-52. PubMed ID: 26308378
[TBL] [Abstract][Full Text] [Related]
5. Signal transducer and activator of transcription family is a prognostic marker associated with immune infiltration in endometrial cancer.
Zhou XY; Dai HY; Zhang H; Zhu JL; Hu H
J Clin Lab Anal; 2022 Apr; 36(4):e24315. PubMed ID: 35244291
[TBL] [Abstract][Full Text] [Related]
6. TIMM8A is associated with dysfunction of immune cell in BRCA and UCEC for predicting anti-PD-L1 therapy efficacy.
Zhu X; Yuan Z; Cheng S; Wang H; Liao Y; Zhou D; Wu Z
World J Surg Oncol; 2022 Oct; 20(1):336. PubMed ID: 36207751
[TBL] [Abstract][Full Text] [Related]
7. Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers.
Raeder MB; Birkeland E; Trovik J; Krakstad C; Shehata S; Schumacher S; Zack TI; Krohn A; Werner HM; Moody SE; Wik E; Stefansson IM; Holst F; Oyan AM; Tamayo P; Mesirov JP; Kalland KH; Akslen LA; Simon R; Beroukhim R; Salvesen HB
PLoS One; 2013; 8(2):e54873. PubMed ID: 23393560
[TBL] [Abstract][Full Text] [Related]
8. A novel risk prediction model of pyroptosis-related genes for the prognosis and immunotherapy response of endometrial cancer.
Liu ZS; Jing CL
Eur Rev Med Pharmacol Sci; 2022 Apr; 26(7):2259-2278. PubMed ID: 35442481
[TBL] [Abstract][Full Text] [Related]
9. Oncogene ATAD2 promotes cell proliferation, invasion and migration in cervical cancer.
Zheng L; Li T; Zhang Y; Guo Y; Yao J; Dou L; Guo K
Oncol Rep; 2015 May; 33(5):2337-44. PubMed ID: 25813398
[TBL] [Abstract][Full Text] [Related]
10.
Zhao Q; Chen G; Yang X; Wang T; Yuan S; Meng Q
Comb Chem High Throughput Screen; 2023; 26(2):330-338. PubMed ID: 35379118
[TBL] [Abstract][Full Text] [Related]
11. Systematic analysis of the oncogenic role of FAM83D across cancers based on data mining.
Geng Y; Liu J; Wang Z; Liu T; Peng X; Huang Y
Cell Cycle; 2023 Apr; 22(8):1005-1019. PubMed ID: 36710419
[TBL] [Abstract][Full Text] [Related]
12. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma.
Wang Z; Xing L; Huang Y; Han P
Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126
[TBL] [Abstract][Full Text] [Related]
13. HIF1α-dependent upregulation of ATAD2 promotes proliferation and migration of stomach cancer cells in response to hypoxia.
Nayak A; Roy AD; Rout N; Singh SP; Bhattacharyya A; Roychowdhury A
Biochem Biophys Res Commun; 2020 Mar; 523(4):916-923. PubMed ID: 31959473
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of AAA-domain-containing protein 2 restrains cancer stem cell properties in esophageal squamous cell carcinoma via blockade of the Hedgehog signaling pathway.
Li N; Yu Y; Wang B
Am J Physiol Cell Physiol; 2020 Jul; 319(1):C93-C104. PubMed ID: 31747529
[TBL] [Abstract][Full Text] [Related]
15. ATAD2 silencing decreases VEGFA secretion through targeting has-miR-520a to inhibit angiogenesis in colorectal cancer.
Hong S; Chen S; Wang X; Sun D; Yan Z; Tai J; Bi M
Biochem Cell Biol; 2018 Dec; 96(6):761-768. PubMed ID: 29958090
[TBL] [Abstract][Full Text] [Related]
16. LHX1 as a potential biomarker regulates EMT induction and cellular behaviors in uterine corpus endometrial carcinoma.
Tian Y; Wen F; Wang S; Lv N
Clinics (Sao Paulo); 2022; 77():100103. PubMed ID: 36116266
[TBL] [Abstract][Full Text] [Related]
17. LINC01589 serves as a potential tumor-suppressor and immune-related biomarker in endometrial cancer: A review.
Chen R; An J; Wang Y; Yang L; Lin Q; Wang Y
Medicine (Baltimore); 2023 Apr; 102(15):e33536. PubMed ID: 37058060
[TBL] [Abstract][Full Text] [Related]
18. KNL1 is a prognostic and diagnostic biomarker related to immune infiltration in patients with uterine corpus endometrial carcinoma.
He K; Li J; Huang X; Zhao W; Wang K; Wang T; Chen J; Wang Z; Yi J; Zhao S; Zhao L
Front Oncol; 2023; 13():1090779. PubMed ID: 36776306
[TBL] [Abstract][Full Text] [Related]
19. Construction of a prognostic model of luteolin for endometrial carcinoma.
Zhao J; Jiao W; Sui X; Zou J; Wang J; Lin Z
Am J Transl Res; 2023; 15(3):2122-2139. PubMed ID: 37056832
[TBL] [Abstract][Full Text] [Related]
20. RNF183 Is a Prognostic Biomarker and Correlates With Tumor Purity, Immune Infiltrates in Uterine Corpus Endometrial Carcinoma.
Geng R; Zheng Y; Zhao L; Huang X; Qiang R; Zhang R; Guo X; Li R
Front Genet; 2020; 11():595733. PubMed ID: 33324448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
